As PDE‐Is block CCL5 secretion by CD8+ T cells and 5AR‐Is the reduce androgen levels, the combination of these drugs may effectively suppress the growth of BECs in the prostate, and therefore, can be considered as a candidate therapeutic approach for BPH patients in the future. Here, CCL5 is linked to benign prostatic hyperplasia.